Posted by Michael Wonder on 27 Feb 2020
NICE recommends new ‘chemotherapy-free’ treatment for lymphoma
27 February 2020 - A new treatment option for patients with previously treated follicular lymphoma (grade 1 to 3A) has been approved by NICE.
The new drug, lenalidomide (Revlimid, Celgene), fights cancer cells in a different way to current treatments, interfering with cell processes to halt the growth of tumours and stopping them from producing their own blood vessels.
Lenalidomide has been recommended for use with rituximab (MabThera, Roche), an anti-CD20 antibody that sticks to cancer cells to help the immune system recognise and kill them.
